Gliadel Wafer advisory committee
Executive Summary
Guilford's Gliadel Wafer will be reviewed by the Oncologic Drugs Advisory Committee on Dec. 4 for treatment of first-line malignant glioma. The ODAC panel was originally scheduled for the afternoon of Sept. 11, but was cancelled due to the terrorist attacks. The meeting will begin at 8 a.m. at the Holiday Inn in Bethesda, Md